NCT05868447

Brief Summary

Concerns about the necessity and risks of blood transfusions have led to the search for new noninvasive monitoring methods. Oxygen reserve index (ORI), one of them, is a dimensionless index ranging from 0.00 (no reserve) to 1.00 (maximum reserve) according to oxygenation reserve status, and it is also a non-invasive and continuous measurement parameter. Some studies have examined ORi as an indicator for early detection of hypoxemia. There are reports in the literature that ORi and Pa02 values measured noninvasively during surgery are early precursors for desaturation and hypoxia.Researces aimed to investigate the relationship between perioperative blood transfusions and ORI in vertebral stabilization surgeries performed by the same surgical team in our clinic.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 15, 2022

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 8, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 22, 2023

Completed
24 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2023

Completed
Last Updated

May 22, 2023

Status Verified

May 1, 2023

Enrollment Period

6 months

First QC Date

May 8, 2023

Last Update Submit

May 18, 2023

Conditions

Keywords

Oxygen reserve indexBlood transfusionvertebrae stabilization surgery

Outcome Measures

Primary Outcomes (1)

  • Intraoperative ORI values

    Monitoring ORI values at the beginning of surgery and values measured every 15 minutes during surgery

    Perioperative process (2-5 hours)

Secondary Outcomes (1)

  • Perioperative blood transfusion prediction

    Perioperative process (2-5 hours)

Interventions

hourly blood gas analysis and hemoglobin and hematocrit control and blood transfusion will be performed when necessary If a low pO2 value is observed in the blood gas, the fi02 values or fresh gas flow will be increased.

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Elective patients planned stabilization surgery

You may qualify if:

  • Patients over 18 years of age in ASA I-III risk class
  • Patients who will undergo vertebral stabilization surgery at 3 levels or more under general anesthesia (lumbar disc herniation, lumbar spinal stenosis, lumbar spondylolisthesis and other lumbar spine pathologies)
  • who are expected to lose \>500 ml of blood
  • Patients who require arterial catheter placement for continuous monitoring of blood pressure and/or analysis of arterial blood gas during surgery

You may not qualify if:

  • Patients with coagulation disorders, thrombocytopenia, liver and kidney disease
  • Patients receiving regular anticoagulant and antiplatelet therapy
  • Patients who will undergo revision surgery
  • Patients who will undergo surgery due to spinal tumor or infection
  • Patients with perioperative tranexamic acid and/or antifibrinolytic use
  • Patients with preoperative hemoglobin values \<12 g/dl in women and \<13 g/dl in men or patients with preoperative anemia due to hemoglobinopathies (e.g. thalassemia, sickle cell disease anemia)
  • Patients with congestive heart failure
  • Inability to attach the sensor due to deformity of the fingers
  • Inability to attach the sensor due to hypoperfusion of the fingers: thalassemia, sickle cell disease anemia)
  • Patients with congestive heart failure
  • Inability to wear the sensor due to deformity of the fingers
  • Patients who would show an inadequate signal due to hypoperfusion of the fingers were excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bursa Training and Research Hospital

Bursa, 16600, Turkey (Türkiye)

Location

Study Officials

  • Asiye A Demirel, MD

    Bursa Yuksek Ihtisas Training and Research Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 8, 2023

First Posted

May 22, 2023

Study Start

December 15, 2022

Primary Completion

June 15, 2023

Study Completion

June 15, 2023

Last Updated

May 22, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will not share

Locations